EQNR Equinor ASA

Equinor ASA: Buy-back of shares to share programmes for employees

Equinor ASA: Buy-back of shares to share programmes for employees

Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management.

Date on which the buy-back programme was announced: 4 February 2026.

The duration of the buy-back programme: 13 February 2026 to 15 January 2027.

Size of the buy-back programme: The total purchase amount under the programme is NOK 1,971,000,000 and the maximum shares to be acquired is 19,600,000 shares, of which up to 7,920,000 shares can be acquired in the period from 13 February 2026 to 15 May 2026, and up to 11,680,000 shares can be acquired in the period from 15 May 2026 to 15 January 2027.

On 15 April 2026, Equinor ASA has purchased a total of 444,297 own shares at the Oslo Stock Exchange at an average price of NOK 357.8681 per share.

Aggregated overview of transactions per day:

DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction value (NOK)
15 April 2026444,297357.8681158,999,723
Previously disclosed buy-backs under the programme (accumulated)



1,068,721




297.5516




317,999,694
Total buy-backs under the programme1,513,018315.2635476,999,417



Following the completion of the above transactions, Equinor ASA owns a total of 64,867,299 own shares, corresponding to 2.54% of Equinor ASA’s share capital, including shares purchased under the previous buy-back programme for the share-based incentive programmes for employees, and shares purchased under Equinor’s disclosed buy-back programmes which will be used to reduce the issued share capital of the company.

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A detailed overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned time period is attached to this report and available at

Further information from

Investor relations

Bård Glad Pedersen, senior vice president Investor Relations,

Media

Sissel Rinde, vice president Media Relations,

Attachment



EN
20/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Equinor ASA

 PRESS RELEASE

Equinor ASA: Notice of annual general meeting 12 May 2026

Equinor ASA: Notice of annual general meeting 12 May 2026 The annual general meeting of Equinor ASA (OSE: EQNR, NYSE: EQNR) will be held Tuesday 12 May 2026 at 15:00 CEST. The annual general meeting will be held in Equinor Business Center, Forusbeen 50, 4035 Stavanger for those attending in person and via Lumi AGM for those attending digitally. Voting will be carried out electronically via Lumi AGM for all shareholders. It is also possible to vote in advance or give proxy. Please see detailed information in the attached notice of the annual general meeting. Further information is also to ...

 PRESS RELEASE

Equinor ASA: Innkalling til ordinær generalforsamling 12. mai 2026

Equinor ASA: Innkalling til ordinær generalforsamling 12. mai 2026 Equinor ASAs (OSE: EQNR, NYSE: EQNR) ordinære generalforsamling finner sted tirsdag 12. mai 2026 klokken 15.00 CEST. Generalforsamlingen vil bli avholdt i Equinor Business Center, Forusbeen 50, 4035 Stavanger for de som deltar fysisk og via Lumi AGM for de som deltar digitalt. Avstemning vil foregå elektronisk via Lumi AGM for alle aksjonærer. Det er også mulig å forhåndsstemme eller gi fullmakt før møtet. Ytterligere informasjon er tilgjengelig i vedlagte innkalling til generalforsamling. Se også informasjon på /generalf...

Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Luis de Toledo Heras
Ahmed Ben Salem
  • Ahmed Ben Salem
Bruno Cavalier ... (+2)
  • Bruno Cavalier
  • Luis de Toledo Heras

ResearchPool Subscriptions

Get the most out of your insights

Get in touch